CN101389623A - 吲哚衍生物的新的盐及其在医药中的用途 - Google Patents

吲哚衍生物的新的盐及其在医药中的用途 Download PDF

Info

Publication number
CN101389623A
CN101389623A CNA2007800069734A CN200780006973A CN101389623A CN 101389623 A CN101389623 A CN 101389623A CN A2007800069734 A CNA2007800069734 A CN A2007800069734A CN 200780006973 A CN200780006973 A CN 200780006973A CN 101389623 A CN101389623 A CN 101389623A
Authority
CN
China
Prior art keywords
salt
ylmethyl
purposes
disease
dementia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800069734A
Other languages
English (en)
Chinese (zh)
Inventor
A·-L·伯格
R·巴特
T·塞布哈图
E·斯塔尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN101389623A publication Critical patent/CN101389623A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2007800069734A 2006-02-28 2007-01-31 吲哚衍生物的新的盐及其在医药中的用途 Pending CN101389623A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77734806P 2006-02-28 2006-02-28
US60/777,348 2006-02-28

Publications (1)

Publication Number Publication Date
CN101389623A true CN101389623A (zh) 2009-03-18

Family

ID=38459317

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800069734A Pending CN101389623A (zh) 2006-02-28 2007-01-31 吲哚衍生物的新的盐及其在医药中的用途

Country Status (5)

Country Link
US (1) US20120115865A1 (https=)
EP (1) EP1991539A4 (https=)
JP (1) JP2009528344A (https=)
CN (1) CN101389623A (https=)
WO (1) WO2007100282A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011066706A1 (zh) * 2009-12-03 2011-06-09 湖南阿斯达生化科技有限公司 一种助焊剂用非卤素活性剂

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101851234A (zh) * 2009-04-03 2010-10-06 上海日馨生物科技有限公司 吡咯喹啉醌锂盐衍生物及其制备方法
EP3920885A1 (en) 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0101765D0 (sv) * 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
GB0124941D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
EP2258687B1 (en) * 2002-02-12 2012-12-26 Glaxosmithkline LLC Nicotinamide derivates useful as P38 inhibitors
SE0302546D0 (sv) * 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
SE0200979D0 (sv) * 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
ATE481397T1 (de) * 2002-04-24 2010-10-15 Merck Sharp & Dohme Modulatoren des östrogenrezeptors
CN100471853C (zh) * 2002-05-29 2009-03-25 伊莱利利公司 苯基-噻吩型维生素d受体调节剂
GB0219153D0 (en) * 2002-08-16 2002-09-25 Pfizer Ltd Substituted glycine derivatives for use as medicaments

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011066706A1 (zh) * 2009-12-03 2011-06-09 湖南阿斯达生化科技有限公司 一种助焊剂用非卤素活性剂
US8853417B2 (en) 2009-12-03 2014-10-07 Hunan Astar Biotechnology Ltd. Non-halogen activating agent used as flux

Also Published As

Publication number Publication date
WO2007100282A8 (en) 2008-01-31
EP1991539A1 (en) 2008-11-19
JP2009528344A (ja) 2009-08-06
EP1991539A4 (en) 2010-08-25
WO2007100282A1 (en) 2007-09-07
US20120115865A1 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
EP1575938B1 (en) Compounds having selective inhibiting effect at gsk3
WO2007120102A1 (en) New substituted oxindole derivatives
EP1458395B1 (en) Medical use of gsk3-inhibiting oxindole derivatives
JP2010535200A (ja) ２−ヒドロキシ−３−［５−（モルホリン−４−イルメチル）ピリジン−２−イル］−１ｈ−インドール−５−カルボニトリル・クエン酸塩の新しい結晶形態
US20080188502A1 (en) New Compounds I
US20120101132A1 (en) New Substituted Oxindole Derivative
JP4475869B2 (ja) 新規なピリミジン化合物
RU2415137C2 (ru) Цитратная соль производного индола, способ ее получения, ее применение и фармацевтическая композиция на ее основе
KR20090122979A (ko) 신규 이미다조[４,５-ｂ]피리딘-７-카르복스아미드 ７０４
EP1406883B1 (en) 4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea and its use in the treatment of conditions associated with glycogen-synthase kinase-3(gsk3)
JP2005526835A (ja) 新規な２−置換−１，３−チアゾール化合物
US20090018130A1 (en) Derivatives of 5-Aryl-1H-Pyrrolo [2, 3B] Pyridine-3-Carboxamide or 5-Aryl-1H-Pyrrolo [2, 3B] Pyridine-3-Carboxylic Acid
CN101389623A (zh) 吲哚衍生物的新的盐及其在医药中的用途
JP2009510162A (ja) 認知症および神経変性疾患を治療するためのグリコーゲンシンターゼキナーゼ阻害剤としての新規な２−フェニル−イミダゾ［４，５−ｂ］ピリジン誘導体
JP2009510160A (ja) アルツハイマー病を予防および／または治療するための医薬の製造におけるピリミジン誘導体の使用
HK1129382A (en) New citrate salt of an indole derivative and its pharmaceutical use
WO2012050517A1 (en) Imidazole substituted pyrimidine having a high gsk3 inhibiting potency as well as pan-kinase selectivity
HK1080856B (en) Compounds having selective inhibiting effect at gsk3

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20090318

C20 Patent right or utility model deemed to be abandoned or is abandoned